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Open access uPurpose: To report on local control and survival after breast conserving therapy (BCT) including three-
dimensional conformal simultaneous integrated boost irradiation (3D-CRT-SIB) and on the inﬂuence of
age on outcome.
Patient and methods: For this study, 752 consecutive female breast cancer patients (stages I–III), treated
with 3D-CRT-SIB at the University Medical Center Groningen from 2005 to 2008, were retrospectively
identiﬁed. Median age was 58.4 (range 26–84) years. The SIB fractionation used was: 28  1.8 Gy (whole
breast) and 28  2.3 Gy or 2.4 Gy (tumour bed). Next to outcome, we estimated the effect of age on the
recurrence-free period (RFP) by multivariate Cox regression survival analysis.
Results: Median follow-up was 41 (range 3–65) months. Local control was 99.6% at 3 years (6 ipsilateral
recurrences). The 3-year locoregional control, RFP and overall survival (OS) rates were 99.2%, 95.5%, and
97.1%, respectively. In multivariate analysis, tumours >2 cm (hazard ratio (HR) 3.11; 95% conﬁdence
interval (CI) 1.57–6.17) and triple negativity (HR 3.03; 95% CI 1.37–6.67) and not age were associated
with impaired RFP.
Conclusions: At 3 years, the 3D-CRT-SIB technique in BCT results in excellent local control and OS. Age
was not a risk factor for any recurrence.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 100 (2011) 215–220Radiotherapy (RT) is considered an integral part of breast con-
serving therapy (BCT) in patients with invasive breast cancer, since
both local control (LC) and overall survival (OS) improved signiﬁ-
cantly by combining breast conserving surgery with RT [1,2]. Cur-
rently, BCT is considered standard of care for patients with stages
I–II disease [3].
Conventional breast RT is delivered to the whole breast and is
often followed by an additional boost dose to the tumour bed
[4]. Breast irradiation with a boost to the tumour bed provides sig-
niﬁcantly higher LC rates than whole breast irradiation alone,
93.8% vs. 89.8% at 10 years, respectively [5]. Since 2005, at our
department, RT after lumpectomy is administered with a three-
dimensional conformal-technique with a hypofractionated
simultaneous integrated boost (3D-CRT-SIB). With the 3D-CRT-SIB
technique [6], whole breast and boost irradiation are combined
in one treatment plan and are given simultaneously. With the
SIB, the mean volume receiving P107% of the breast dose was re-
duced by 20%, the mean volume outside the boost PTV receivingdiation Oncology, University
Groningen, The Netherlands.
ro).
nder the Elsevier OA license.P95% of the boost dose was reduced by 54%, and the mean heart
and lung dose were reduced by 10% compared to the sequential
boost technique [6]. Due to the higher dose per fraction to the tu-
mour bed, the overall treatment time can be reduced with 2 weeks,
which adds substantially to patient convenience. In addition, we
showed that the 3D-CRT-SIB was superior to the sequential
boost-technique with respect to unintended excessive dose to
the area outside the boost [6]. Despite the somewhat higher dose
per fraction to the boost area, acute toxicity after 3D-CRT-SIB
was mild and remained within acceptable limits [6].
Studies reporting on BCT show that treatment outcome in terms
of LC is signiﬁcantly worse in younger patients compared to older
patients [7–10]. In the European Organisation for Research and
Treatment of Cancer (EORTC) study 22881-10882, the absolute
beneﬁt of a boost in terms of local control was most pronounced
in young patients [5]. Differences exist between the aforemen-
tioned 3D-CRT-SIB technique, and the techniques that were used
in the EORTC study 22881-10882. In contrast to the EORTC study,
all patients treated with 3D-CRT-SIB were planned using a com-
puter tomography (CT) scan which may improve reconstruction
of the exact location and volume of the boost area. Furthermore,
CT-based planning provides more accurate information on the dose
Table 1
Patient and tumour characteristics (n = 752).
Characteristic n (%)
Age at diagnosis (y)
650 204 (27.1)
>50 548 (72.9)
BRCA 1 or 2 mutation
Absent 22 (2.9)
Present 12 (1.6)
216 3D-CRT-SIB in breast cancer: Local controldistribution and offers the opportunity to optimise dose homoge-
neity and dose conformity. As the local recurrence rate is expected
to be highest in younger patients, the question arises whether such
a difference would also be present after breast irradiation with the
3D-CRT-SIB technique.
Therefore, the purpose of this paper was to evaluate the clinical
outcome of a consecutive series of patients with invasive breast
cancer treated with the 3D-CRT-SIB as part of BCT and to investi-
gate the inﬂuence of age on treatment outcome.Unknown 718 (95.5)
Pathological T-stage
T1 561 (74.6)
TP 2 191 (25.4)
Pathological N-stage
N0 522 (69.4)
N1 190 (25.3)
N2+ 37 (4.9)
Nx 3 (0.4)
Histology
Invasive ductal 658 (87.4)
Invasive lobular 66 (8.8)
Other 28 (3.7)
Multifocality
No 728 (96.8)
Yes 24 (3.2)
Status resection margins
Negative 635 (84.4)
(Focally) positive 109 (14.5)
Missing 8 (1.1)
Differentiation grade
I/II 550 (73.1)Patients and methods
Study population
The study population was composed of 752 consecutive female
invasive breast cancer patients (stages I–III) treated with breast
conserving surgery. All patients were treated with postoperative
RT using 3D-CRT-SIB at the department of Radiation Oncology of
the University Medical Center Groningen between January 2005
and January 2008. Excluded were male patients, patients with a
history of invasive cancer (except non-melanoma skin cancer or
carcinoma in situ of the cervix), previous irradiation to the thorax,
patients diagnosed with synchronous contralateral breast cancer
(i.e., breast cancer diagnosed in both breasts simultaneously or
within a 3-month period of diagnosis of the ﬁrst tumour), and pa-
tients treated with neo-adjuvant chemotherapy. The median age at
diagnosis was 58.4 (range 26–84) years. There were 204 patients
(27.1%) aged 50 years or younger at time of diagnosis. Patient, tu-
mour and treatment characteristics are listed in Table 1.III 193 (25.7)
Missing 9 (1.2)
Lymphovascular invasion
Absent 696 (92.6)
Present 56 (7.4)
Extensive DCIS
Absent 684 (91.0)
Present 68 (9.0)
Extra nodal growth
Absent 694 (92.3)
Present 58 (7.7)
Oestrogen receptor (ER)
Positive 595 (79.1)
Negative 126 (16.8)
Missing 31 (4.1)
Progesterone receptor (PR)
Positive 514 (68.4)
Negative 205 (27.3)
Missing 33 (4.4)
HER2 receptor
Positive 69 (9.2)
Negative 626 (83.2)
Missing 57 (7.6)Data collection
Patient, tumour and treatment-related characteristics as well as
follow-up data were collected retrospectively from the medical
ﬁles. The following data were collected: age at diagnosis, informa-
tion regarding primary surgery, adjuvant chemotherapy and hor-
monal treatment, regional RT, tumour recurrence, distant
metastases, and death. Data regarding tumour size, lymph node
status, number of metastatic lymph nodes, positive apical lymph
nodes, histologic diagnosis and grade, presence of lymphovascular
invasion and extensive ductal carcinoma in situ (DCIS), multifocal-
ity, resection margin status, and receptor status were obtained di-
rectly from the pathology report. Patients were staged according to
the TNM classiﬁcation system (IUCC 2002) [3]. In 52 cases with
missing data (mainly follow-up), the general practitioner was con-
tacted for additional information. In 42 cases (80.8%), the addi-
tional follow-up data were provided. Data were entered in a
database and maintained by a data manager. Data collection of
the present study was conducted under compliance of the hospital
institutional review board regulations.Triple negativea
No 659 (87.6)
Yes 93 (12.4)
Adjuvant chemotherapy
No 486 (64.6)
Yes 266 (35.4)
Adjuvant hormonal therapy
No 461 (61.3)
Yes 291 (38.7)Toxicity scoring
During routine follow-up at our department, the physician-
rated, late toxicity was prospectively assessed according to the
Common Terminology Criteria of Adverse Events version 3.0
(CTCAE v3.0) [11]. Routine out-patient visits were made yearly,
from the ﬁrst year to 5 years after RT.Adjuvant trastuzumab
No 715 (95.1)
Yes 37 (4.9)
Regional radiotherapy
No 707 (94.0)
Yes 45 (6.0)Deﬁnitions
Because itwas not possible to differentiate between a true LR and
newprimary tumours in the ipsilateral breast, LRwas deﬁned as any
recurrence, either invasive or in situ carcinoma, in the ipsilateral
breast or overlying skin. Regional recurrence (RR) was deﬁned as
Table 1 (continued)
Characteristic n (%)
Boost dosage
Low (64.4 Gy) 573 (76.2)
High (67.2 Gy) 179 (23.8)
Abbreviations: DCIS: ductal carcinoma in situ; HER2: human epidermal growth
factor receptor 2.
a ER negative, PR negative, and HER2 negative.
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mammary lymph nodes without clinical or radiologic evidence of
distant metastases. Locoregional recurrence (LRR) was deﬁned as
either LR or RR. LRRwas considered an event if thiswasnot preceded
by distant metastases (i.e., ﬁrst event). In case of simultaneous LRR
and distant metastases, the locoregional event was considered the
ﬁrst event in the analyses.
Distant metastases were deﬁned as all cancers, spread from the
primary tumour, occurring at sites other than local or regional
sites. Death of disease was deﬁned death preceded by LRR or dis-
tant metastases. Overall survival considered deaths of any cause.
Endpoints were calculated as the interval between pathological
diagnosis of primary breast cancer and the event of interest or date
of last follow-up. As few LRR events were expected, an additional
endpoint was deﬁned to investigate disease progression, including
the recurrence-free period (RFP) deﬁned as the time of date of
diagnosis until any recurrence (LRR or distant metastases). RFP was
presented as 1 minus the cumulative incidence of any recurrence.
Multifocality was considered positive as two or more foci of the
invasive component were present in the pathological specimen.
Resection margins were considered microscopically involved in
case of a positive resection margin or a margin of less than
1 mm. Otherwise, the margin was considered to be tumour free.
DCIS was classiﬁed as extensive if 10 or more ducts were involved.
The apical lymph node was deﬁned as the most cranial positioned
lymph node in the axillary dissection specimen as marked by the
surgeon.Radiotherapy
Patients were treated with 3D-CRT-SIB as part of BCT. This tech-
nique and choice of fractionation has been described in more detail
by van der Laan et al. [6]. Brieﬂy, with the SIB technique, breast and
boost beams are combined in one integrated treatment plan, i.e.,
patients are treated with the same plan each fraction throughout
the entire course of treatment. Fractionation schemes used were
28 daily fractions of 1.8 Gray (Gy) to the whole breast PTV and
2.3 Gy (76.2%) or 2.4 Gy (23.8%), in case of involved or focally posi-
tive resection margins, to the boost planning target volume (PTV),
adding up to a total dose of 64.4 Gy or 67.2 Gy. These fractionation
schemes are biologically equivalent to the sequential boost-tech-
nique comprising 25 fractions of 2 Gy to the whole breast PTV fol-
lowed by a boost irradiation in 8 or 10 fractions, using an a/b ratio
of 10 Gy for tumour response, based on the linear-quadratic cell
survival model [12].
The breast clinical target volume (CTV) included the glandular
breast tissue of the ipsilateral breast, excluding the major pectoral
muscle, the ribs and the skin. The tumour bed CTV was delineated
guided by the presence of the surgical clips, hematoma, seroma
and/or other surgery-induced changes. Breast and boost CTVs were
expanded with a margin of 5 mm to generate the breast and boost
PTVs. For the breast PTV, a margin of 10 mm was used in the cra-
nial and caudal directions. The 3D-CRT-SIB treatment plans con-
sisted of tangential breast beams with multileaf collimator (MLC)
shielding conformal to the breast PTV. In general, one or more
boost beams with a non-tangential beam-direction were addedconformal to the boost PTV. Beam weights, wedge fractions and
MLC settings for all beams were manually adjusted in such a
way that the 95%-isodose closely encompassed the PTVs in 3
dimensions, and volumes receiving P107% of the dose prescribed
to the PTVs were minimized. No speciﬁc constraints for organs at
risk were used. Beam directions, multileaf collimator settings,
beam shapes and beam weights were manually optimised to min-
imise the dose to heart, lung and breast tissue as much as possible
without compromising target coverage. Field in ﬁeld segments
were used to improve dose homogeneity and dose-to-target con-
formity. Attempts were made to cover at least 98% of virtual breast
and boost PTVs (original PTVs excluding the build-up region) with
95% of the prescribed dose. All beams were delivered with a linear
accelerator using 6 or 15 MV photons.
Regional RT, including the axillary, supra and infraclavicular no-
dal areas, with or without the internal mammary nodes (IMN), was
indicated in case of more than 3 axillary lymph node metastases or
in case of a positive apical lymph node (total n = 45; 6%). Indica-
tions for IMN-RT were medial located tumours with indication
for regional RT, pathological positive IMN sentinel node, and posi-
tive ﬂow to an IMN lymph node, which was not removed during
surgery.Systemic therapy
Patients with node-positive disease and high risk node-negative
tumours were treated with adjuvant systemic therapy according to
national guidelines [3]. Risk classiﬁcation was based on tumour
size, grade, hormonal receptor status and age. Chemotherapy con-
sisted of 5-ﬂuorouracil, epirubicin and cyclophosphamide (FEC) in
260 (97.7%) patients. Six patients received a combination of
adriamycin and cyclophosphamide (AC). In this series, none of
the patients was treated with taxane-based chemotherapy. In gen-
eral, in node-positive disease, chemotherapy was administered
ﬁrst followed by RT, whereas in node-negative patients, RT was gi-
ven ﬁrst. The treatment sequence was based on regional consensus
of opinion. Adjuvant hormonal therapy was indicated for all inter-
mediate and high risk hormonal receptor-positive patients.
Depending on menopausal status, tamoxifen or aromatase inhibi-
tors were given. For patients receiving chemotherapy, trastuzumab
was recommended for all patients with tumours overexpressing
the human epidermal growth factor receptor 2 (HER2) [3].Statistical analysis
Contingency tables were used to present the patient, tumour
and treatment-related characteristics, number of ﬁrst events and
second cancers (i.e., malignancy not related to a recurrence or pri-
mary tumour). Furthermore, the observed proportions of late tox-
icities are reported.
The unadjusted 3-year actuarial rates of LC, locoregional control
(LRC), RFP, and OS and corresponding 95% conﬁdence intervals
(CIs) were calculated using the Kaplan–Meier method. Given the
median follow-up duration, we presented the 3-year rates. The
dataset was stratiﬁed according to age (650 and >50 years) and
outcomes were compared with the log rank test.
Univariate analyses and multivariate analysis were performed
using the Cox proportional hazard model to identify prognostic
factors for RFP. The covariates that were univariately related to
the endpoint (p < 0.10) were entered in the multivariate analysis.
Adjusted hazard ratios (HRs) and 95% CIs were calculated. In addi-
tion to the dichotomized covariate of age at diagnosis (650 and
>50 years), we explored the impact of other age groups in the anal-
ysis, by categorizing age in 4 subgroups (640, 41–50, 51–60 and
>60 years). Due to the high correlation between both oestrogen
receptor status and triple negativity (i.e., oestrogen receptor (ER)
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lymph node status and regional RT (Pearson’s R > 0.8), only triple
negative receptor status and lymph node status were included in
the multivariate analysis.
To explore the impact of competing risks on outcome, two sen-
sitivity analyses were performed. First, all patients who developed
a second cancer during follow-up were excluded from the analysis
and second, all patients who had a non-breast cancer related death
were excluded.
All tests were two-sided and probability values of <0.05 were
considered to be statistically signiﬁcant. The analyses were per-
formed using the SPPS software package, version 16.0 for Windows
(SPSS, Chicago, IL, USA).Results
Patterns of failure
Median follow-up was 41 (range 3–65) months. The patterns of
failure are listed in Table 2. During follow-up, 6 patients developed
an ipsilateral LR with a median time to LR of 33.5 (range 13–61)
months, including 4 invasive tumours and 2 pure DCIS. Five out
of these recurrences were in-breast recurrences and were treated
with salvage mastectomy. So far, these 5 patients remained dis-
ease-free. After 14 months of follow-up, 1 out of these 6 patients
developed lymphangitis carcinomatosa in the treated breast with
concurrent supraclavicular and distant metastases. She was treated
with palliative chemotherapy, but died within 2 years.
In the 2 patients with a pure DCIS LR, these were located outside
the boost ﬁelds. In 2 other patients with an invasive LR, the LRs
were localized just beneath the scar of the primary lumpectomy
and within the boost PTV. The ﬁfth invasive LR was seen in a pa-
tient with a multifocal primary tumour with extensive DCIS. The
LR was present diffusely through the whole breast, with massive
lymphangioinvasion.
In total, 5 patients developed an isolated RR. In 2 patients, this
RR was localized in the axilla, in 1 patient in the supraclavicular re-
gion, in 1 patient in the IMN and in 1 patient in both supraclavic-
ular and IMN simultaneously. None of these patients had been
treated with regional RT and all RRs were located outside the pri-
mary radiation ﬁelds. Supraclavicular recurrences with concurrent
distant metastases were observed in 2 patients. One of these 2 pa-
tients died of disease. During follow-up, 3 patients with a RR had
disease progression with distant metastases. Two of these patients
eventually died.
Distant metastases as ﬁrst event developed in 27 patients, of
whom 11 (40.7%) subsequently died. In total, 15 patients died of
disease progression.
Eleven patients died of other causes, including cerebrovascular
events (n = 2), liver cirrhosis (n = 1), suicide (n = 1), secondary
malignancies (n = 5) and unknown causes (n = 2), respectively.Table 2
Patterns of failure (n = 752).
First event n (%)
Local recurrence (LR)a 6 (0.8)
Regional recurrence (RR)b 8 (1.1)
Distant metastases (DM) 27 (3.6)
Death of disease 15 (2.0)
Death of all causes 26 (3.5)
Secondary malignancy
Contralateral breast cancer 11 (1.5)
Ovarian cancer 1 (0.1)
Other 16 (2.1)
Median time since diagnosis (mos) (range) 41 (3–65).
a One patient developed LR, RR and DM simultaneously.
b Two patients developed RR and DM simultaneously.Primary outcomes
The 3-year LC was 99.6% (95% CI 99.5–99.6), RFP 95.5% (95% CI
95.4–95.5), and OS 97.1% (95% CI 97.0–97.1), respectively. In Figs. 1
and 2, the Kaplan–Meier curves of LC and OS are shown. The actu-
arial 3-year rates, comparing young and old patients (650 and
>50 years at diagnosis) including the 95% CIs of all endpoints and
the corresponding p-values of the log-rank test are listed in Table
3. No signiﬁcant differences in clinical outcome were found accord-
ing to age.Secondary malignancies
Secondary malignancies developed in 28 patients (3.7%). In 11
cases, the secondary primary tumour was located in the contralat-
eral breast. One patient (3.6%) developed oesophageal cancer; 7
other patients (25.0%) developed cancer elsewhere in the gastro-
intestinal tract; 3 patients (10.7%) lung cancer; 2 patients (7.1%)
head and neck cancer; 2 patients acute myeloid leukemia; 1 patient
ovarian cancer and 1 patient endometrial carcinoma. Five patients,
who developed a second malignancy other than contralateral lo-
cated breast cancer, died of this second cancer.Late toxicity
Toxicity scores were available in 612 patients (81.4%). The pro-
portion of patients with grade 2 or higher ﬁbrosis in the breast (i.e.,
ﬁbrosis in the boost area and/or non-boost area) (n = 49), gradeP2
telangiectasia in the treated breast (n = 19), breast oedema (n = 63),
any pain to the thoracic wall (n = 42), and rib fractures (n = 2) were
observed in 9.1%, 3.2%, 10.7%, 7.1%, and 0.4%, respectively. In total,
three cases (0.5%) of pneumonitis grade 1 were reported. No fatal
cardiac events were observed. One patient treated for right-sided
breast cancer developed a myocardial infarction, while another
patient treated for left-sided breast cancer was diagnosed with
cardiac arrhythmia.Univariate analysis
Because of the low number of events, univariate and multivari-
ate analyses were only performed for RFP. In univariate analysis,
signiﬁcantly worse RFP was observed in patients with pathological
tumour size larger than 2 cm (HR 3.94; 95% CI 2.11–7.34, p < 0.001),
patients with more than 3 positive lymph nodes (HR 3.22; 95% CI
1.22–8.50, p = 0.018), grade III tumours (HR 2.90; 95% CI 1.56–
5.41, p = 0.001), tumours not expressing oestrogen receptor (HR
3.23; 95% CI 1.70–6.14, p < 0.001), tumours with triple negativeFig. 1. Kaplan–Meier curve of local control and actuarial 3-year rate of included
patients treated with breast conserving surgery and 3D-CRT-SIB after invasive
breast cancer.
Fig. 2. Kaplan–Meier curve of overall survival and actuarial 3-year rate of included
patients treated with breast conserving surgery and 3D-CRT-SIB after invasive
breast cancer.
Table 3
Actuarial 3-year survival rates according to age at diagnosis and overall.
Endpoint 650 >50 Total
% (95%
CI)
% (95%
CI)
p-
Valuea
% (95%
CI)
Local control 99.5 (99.4–
99.5)
99.6 (99.5–
99.6)
0.98 99.6 (99.5–
99.6)
Locoregional
control
99.0 (98.9–
99.0)
99.2 (99.1–
99.2)
0.61 99.2 (99.1–
99.2)
Recurrence-
free period
96.3 (96.2–
96.3)
95.2 (95.1–
95.2)
0.76 95.5 (95.4–
95.5)
Overall
survival
98.5 (98.4–
98.5)
96.6 (96.5–
96.6)
0.25 97.1 (97.0–
97.1)
Abbreviations: CI: conﬁdence interval.
a Compared with log-rank test.
Table 4
Multivariate model of recurrence-free period.a
Characteristic HR (95% CI) p-Value
Pathological T-stage
T1 1
TP 2 3.11 (1.57–6.17) 0.001b
Pathological N-stage
N0 1
N1 1.19 (0.56–2.56) 0.65
N2+ 2.18 (0.76–6.25) 0.15
Differentiation grade
I/II 1
III 1.52 (0.70–3.31) 0.29
Triple negativec
No 1
Yes 3.03 (1.37–6.67) 0.006
Adjuvant chemotherapy
No 1
Yes 0.82 (0.38–1.77) 0.62
Abbreviations: HR: hazard ratio; CI: conﬁdence interval.
a Adjusted for all covariates in the model.
b Bold values signify p < 0.05.
c Oestrogen receptor negative, progesterone receptor negative and human epi-
dermal growth factor receptor 2 negative.
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tients who received adjuvant chemotherapy (HR 2.14; 95% CI 1.15–
3.99, p = 0.02) or regional RT (HR 2.98; 95% CI 1.25–7.14, p = 0.01).
Young age was no risk factor for RFP, neither among patients of
650 years (HR 1.12; 95% CI 0.56–2.24, p = 0.76), nor among patients
640 years of age (HR 0.63; 95% CI 0.20–1.91, p = 0.53).Multivariate analysis
Tumour size and triple negative receptor status were the only
two independent prognostic factors for RFP (Table 4). Patients with
tumours larger than 2 cm had worse RFP than patients with tu-
mours smaller than 2 cm. Furthermore, RFP was impaired in pa-
tients with triple negative receptor status compared to those
with non-triple negative status.
Excluding the secondary malignancies or non-breast cancer re-
lated deaths from the analysis did not change results and therefore
both factors were not considered signiﬁcant competing risks (data
not shown).
Discussion
In this large consecutive series of patients treated with breast
conserving surgery and hypofractionated 3D-CRT-SIB irradiation,
local control at 3 years was 99.6%, with only a few cases of grade
2 or higher late toxicity. The 3-year LRC and OS were 99.2% and
97.1%, respectively.
In 2001, Bartelink et al. [13] published the results of the ran-
domized EORTC study 22881-10882, with one of the largest series
treated with whole breast irradiation and a sequential boost of
16 Gy (n = 2661). The radiotherapy boost was delivered in variousways (external beam electrons, photons or iridium-192 brachy-
therapy). Radiotherapy was generally not given with the use of
modern 3D CT-based radiotherapy techniques. At 3 years of fol-
low-up, LC and OS among patients who received a boost dose in
that study were 97.9% (95% CI 97.6–98.2) and 93.8% (95% CI not re-
ported), respectively. After publication of these results, whole
breast irradiation with a sequential boost of 16 Gy was introduced
as standard of care in the Netherlands. The current 3D-CRT based
study shows somewhat higher LC rates compared to the EORTC
study by Bartelink et al.
McDonald et al. recently reported on a series of 282 invasive
breast cancer patients treated with Intensity-Modulated Radiation
Therapy (IMRT)-SIB after breast conserving surgery [14], and found
8 ipsilateral in-breast LR and 4 RR after a median follow-up of
33 months. The 3-year LRC and OS were 97.1% and 97.0% (95%
CIs not reported), respectively. The characteristics of the study
population were more or less comparable with that of the present
series. Hence, the 99.6% LC rate in this consecutive series of breast
cancer patients is promising and in line with the results found by
others. Acute skin toxicity reported by others was also comparable
to the toxicity we observed in the ﬁrst 90 patients treated with 3D-
CRT-SIB at our institution [6].
Overall, our late toxicity rates seem to be acceptable; at 3 years,
the incidence of moderate to severe (i.e., grade P2) ﬁbrosis in the
breast was lower than the 20% observed in the EORTC study
22881-10882 [5]. Physician-rated late toxicity after the use of
SIB-RT was reported in a small prospective non-randomized study
by Raiyawa et al. [15]. In that study 60 patients were treated with
whole breast irradiation (25 fractions of 2 Gy) combined with
either a sequential electron boost of 5 fractions of 3 Gy (in total
15 Gy) or a SIB-electron boost of 25 fractions of 0.4 Gy (10 Gy in to-
tal) to the tumour bed [15]. At 7 months of follow-up, grade P2
ﬁbrosis was reported in 10% of patients, which is comparable to
our results. No gradeP2 telangiectasia, breast oedema, or rib frac-
tures were observed. Most importantly, the toxicities were compa-
rable between the two studied groups.
Young age at diagnosis (650 years) was no risk factor for disease
progression or any other endpoint considered in current series of
breast cancer patients treated with BCT. In several other studies,
young age was associated with worse clinical outcome, such as LC
and survival after both BCT and mastectomy [7–10,13,16]. The lack
of impact of age on disease recurrence in our series could be
220 3D-CRT-SIB in breast cancer: Local controlexplained by a number of factors. The small number of events in our
series may have limited the ability to detect differences between
groups, but could also indicate a safe selection of patients for BCT.
Furthermore, the increaseduse of adjuvant systemic therapy, partic-
ularly in high risk node-negative patients might explain this lack of
impact of age. In an overview of the randomized trials by the Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG), both single
agent and polychemotherapy have been shown to improve LC and
survival signiﬁcantly, with the largest gain in the youngest age
groups (i.e., patients <50 years) [17,18]. Finally, another factormight
be the boost dose, which was given to all patients. In our series, all
patients received a boost, uniformly applied, which has been shown
to further decrease the risk of local recurrences [5].
Another explanation for the lack of impact of age in our series
might be the strong association between triple negative receptor
status and disease progression. Triple negative receptor status re-
sulted in a threefold increase of disease progression risk. Triple
negative receptor status is strongly associated with poor clinical
outcome [19,20]. In general, young women have more frequently
triple negative tumours [19,21]. This could therefore be the
biological explanation for worse outcome related to young age
[7–10,13,16]. The only study investigating the impact of age inde-
pendently of triple negative status is a retrospective study of 375
breast cancer patients in which both triple negative disease and
patients under 35 years of age were independent risk factors for
any recurrence [22]. This study by Kwon et al. was hampered by
the fact that 31.5% of the patients did not receive any radiotherapy
after breast conserving surgery. Furthermore, it is not clear
whether the other patients received a boost to the tumour bed.
Therefore, part of the local recurrences, especially in young women
might be caused by inadequate local treatment. This could explain
the relation found between age and recurrence.
One disadvantage of our series is the relatively short follow-up
with a median of 41 months. Although it is known that there is no
plateau phase for in-breast recurrences, most true local recur-
rences develop in the ﬁrst 3 to 4 years after treatment [23].
Next to application of the SIB in 3D-CRT, the SIB can be used
combined with IMRT (IMRT-SIB). A potential advantage of the
IMRT-SIB over 3D-CRT-SIB is the possibility of reducing the dose
in organs at risk (OARs), such as the heart, lungs and the contralat-
eral breast. However, others showed that, in general, the same
reductions of calculated dose to these OARs could be achieved in
3D-CRT-SIB compared to IMRT-SIB [24–26]. The combination of
easy implementation of the 3D-CRT-SIB without increasing the
complexity and time involved with radiation treatment planning,
the relatively mild acute skin toxicity [6] and the excellent results
found in this series, justify the implementation of 3D-CRT-SIB as an
alternative for breast-IMRT-SIB.
In conclusion, 3D-CRT-SIB as part of BCT results in excellent local
control, LRC and OS rates even in the younger population without
excess in long term toxicity. Although these results are promising,
longer follow-up is required to further conﬁrm these results.Conﬂicts of interest statement
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